Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus XYZAL.
FEXOFENADINE HYDROCHLORIDE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic symptoms without significant central nervous system penetration.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
60 mg orally twice daily or 180 mg orally once daily; maximum 180 mg/day.
5 mg orally once daily in the evening.
None Documented
None Documented
14.4 hours in healthy adults; prolonged in renal impairment (up to 58 hours in end-stage renal disease) requiring dose adjustment.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily fecal (80%) with approximately 11% renal excretion of unchanged drug. Biliary excretion contributes to fecal elimination.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine